Novo Nordisk Launches Wegovy Weight-Loss Pill in US, Intensifying Price War

Novo Nordisk has launched the first GLP-1 weight-loss pill in the United States.
The once-daily Wegovy pill is priced well below injectable alternatives.
It is the first and only pill that mimics the GLP-1 hormone to suppress appetite.
Self-paying patients can access the starting dose for $149 per month.
Injectable GLP-1 treatments typically cost around $1,000 per month.
The pill offers a needle-free option that may appeal to more patients.
Novo hopes the launch will help regain market share lost to competitors.
Rival Eli Lilly markets injectable drugs Mounjaro and Zepbound.
Both companies have recently cut prices for cash-paying patients.
The Wegovy pill is currently approved only in the US, with wider reviews ongoing.